Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$7.64 -2.6%	$6.79	$1.77 ▼ $8.72	$698.87M	-0.46	1.32 million shs	880,307 shs
CRDF Cardiff Oncology	$2.39 -0.8%	$3.52	$2.09 ▼ $5.64	$160.33M	1.54	3.19 million shs	1.23 million shs
DAWN Day One Biopharmaceuticals	$6.10 +1.2%	$6.70	$5.64 ▼ $16.76	$617.66M	-1.26	2.01 million shs	2.12 million shs
VIR Vir Biotechnology	$4.30 -1.1%	$5.30	$4.25 ▼ $14.45	$604.29M	1.18	1.05 million shs	1.54 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-2.55%	-1.04%	+5.52%	+65.73%	+306.38%
CRDF Cardiff Oncology	-0.83%	-9.47%	-41.42%	-10.15%	+11.68%
DAWN Day One Biopharmaceuticals	+1.16%	-8.27%	-12.86%	-5.43%	-52.04%
VIR Vir Biotechnology	-1.15%	-14.51%	-27.49%	-15.52%	-48.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	2.8251 of 5 stars	4.5	1.0	1.0	2.5	0.6
CRDF Cardiff Oncology	1.9505 of 5 stars	3.4	0.0	3.2	1.7	0.6
DAWN Day One Biopharmaceuticals	2.809 of 5 stars	3.6	3.0	3.0	2.5	0.0
VIR Vir Biotechnology	2.8198 of 5 stars	3.4	1.0	2.1	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	53.80% Upside
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	322.59% Upside
DAWN Day One Biopharmaceuticals	3.14	Buy	$25.33	315.30% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	603.49% Upside

Current Analyst Ratings Breakdown

Latest CRDF, VIR, AMLX, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	7.79	N/A	N/A	$2.40 per share	3.18
CRDF Cardiff Oncology	$680K	233.83	N/A	N/A	$0.88 per share	2.72
DAWN Day One Biopharmaceuticals	$131.16M	4.76	N/A	N/A	$4.50 per share	1.36
VIR Vir Biotechnology	$74.21M	8.05	N/A	N/A	$6.82 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-80.33%	-68.03%	N/A
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	8/14/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.00	N/A	N/A	N/A	-2,895.94%	-50.22%	-40.78%	N/A

Latest CRDF, VIR, AMLX, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	N/A	N/A	N/A	$0.10 million	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.72	-$0.80	-$0.08	-$0.80	$2.38 million	$1.21 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
CRDF Cardiff Oncology	N/A	4.42	4.42
DAWN Day One Biopharmaceuticals	N/A	9.65	10.55
VIR Vir Biotechnology	N/A	7.01	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
CRDF Cardiff Oncology	16.29%
DAWN Day One Biopharmaceuticals	87.95%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
CRDF Cardiff Oncology	7.70%
DAWN Day One Biopharmaceuticals	6.20%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
VIR Vir Biotechnology	580	138.92 million	116.12 million	Optionable

CRDF, VIR, AMLX, and DAWN Headlines

Recent News About These Companies

Short Interest in Vir Biotechnology, Inc. (NASDAQ:VIR) Rises By 50.7%

August 9 at 2:43 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% Following Weak Earnings

August 8 at 11:22 AM | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% After Earnings Miss

August 8 at 3:09 AM | americanbankingnews.com

Vir Biotechnology Reports Q2 2025 Financial Results

August 7 at 4:43 AM | msn.com

Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum

August 7 at 4:43 AM | msn.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Short Interest Update

August 7 at 2:26 AM | marketbeat.com

Vir (VIR) Q2 Revenue Drops 61%

August 7 at 2:00 AM | fool.com

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

August 6 at 12:01 AM | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

August 6 at 7:51 PM | zacks.com

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6 at 4:05 PM | businesswire.com

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 6 at 8:05 AM | businesswire.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $109,780.00 in Stock

August 5, 2025 | marketbeat.com

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $30.25

August 4, 2025 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Brokerages

August 1, 2025 | marketbeat.com

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks

July 31, 2025 | genengnews.comG

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025 | businesswire.com

Allianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

July 30, 2025 | zacks.com

Vir Biotech begins patient dosing in phase 1 trial of EGFR-targeting PRO-XTEN dual-masked T-cell engager VIR-5525 to treat solid tumours

July 26, 2025 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
A New AI Tailwind Could Come to Boost Taiwan Semiconductor Stock
By Gabriel Osorio-Mazilli | August 5, 2025
View A New AI Tailwind Could Come to Boost Taiwan Semiconductor Stock

CRDF, VIR, AMLX, and DAWN Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$7.64 -0.20 (-2.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.58 -0.06 (-0.85%)

As of 08/8/2025 05:42 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Cardiff Oncology NASDAQ:CRDF

$2.39 -0.02 (-0.83%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+1.05%)

As of 08/8/2025 07:53 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.10 +0.07 (+1.16%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.29 +0.19 (+3.05%)

As of 08/8/2025 07:55 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Vir Biotechnology NASDAQ:VIR

$4.30 -0.05 (-1.15%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.30 0.00 (-0.12%)

As of 08/8/2025 04:35 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time